anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:To prepare a health drink, having a nutritive value and nice taste, and containing an extract from a fruit body of the genus Grifola essentially without forming a precipitate even on storage for a long term, by storing the extract from the fruit body of the genus Grifola at a low temperature, and removing the deposited sediment. CONSTITUTION:A fruit body of the genus Grifola, e.g. Grifola albicans, Imaz. or Grifola fondosa S.F. Gray, is ground, and the active constituent is extracted with water in an amount of 5-15 times that of the fruit body under heating at 70- 100 deg.C. Insoluble residues are filtered off, and the resultant extract is allowed to stand at a low temperature of 1-10 deg.C for 24hr or longer. After removing the formed sediment, the supernatant liquid is directly packaged or concentrated and if desired mixed with a saccharide, organic acid, etc. and packaged.
Dose Level 2: Carfilzomib IV (20 mg/m\^2) D1\&D2 of C1 and carfilzomib IV (45 mg/m\^2)D8, D9, D15, D16 of C1. Carfilzomib IV (45 mg/m\^2) D1, D2, D8, D9, D15, D16 C2-6. Carfilzomib IV (45 mg/m\^2)D1, D2, D8, D15, D22 C7+. PLD IV (30 mg/m\^2)D8 C1-6.
Patients receive neratinib PO QD on days 1-21, paclitaxel IV over 1-3 hours on days 1, 8, and 15, pertuzumab IV over 1 hour on day 1, and trastuzumab IV over 1-2 hours on day 1. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients without progression or excessive toxicity with metastatic disease may receive up to 4 additional courses and with locally advanced disease may receive up to 2 additional courses.
Currently, few studies have demonstrated the relationship between total serum IgE (T-IgE) and acute exacerbation chronic obstructive pulmonary disease (AECOPD). In this study, T-IgE in AECOPD patients were investigated and jointly analyzed with the clinical characteristics. AECOPD patients hospitalized from July 2018 to July 2019 were included in this study. In this patient cohort, clinical information was investigated. Routine blood tests, C-reactive protein and T-IgE levels of patients were determined along with blood gas analysis. The length of hospital stays, mechanical ventilation during hospitalization, ICU admission, glucocorticoid related clinical information were recorded. A total of 285 AECOPD patients were included in this study, which consisted of a high proportion of males. Of all patients, 49.82% patients exhibited higher T-IgE levels. Based on the reference T-IgE value 60 kU/L, patients were divided into high T-IgE group with T-IgE > 60 kU/L, and low T-IgE group with T-IgE ≤ 60 kU/L. There was no significant difference in the dosage of glucocorticoid between the two groups. Patients in the high T-IgE group had shorter hospital stays and lower probability of mechanical ventilation compared to the low T-IgE group. After adjustment for confounding factors, T-IgE was negatively correlated with the length of hospital stays. AECOPD patients with elevated T-IgE had shorter hospital stays and lower risks of mechanical ventilation and ICU admission. Our results showed that T-IgE might play an important role on evaluating the condition and guiding for treatment decisions in AECOPD patients.
The present invention relates to a self-quarantine management system for preventing spread of infectious diseases using hybrid indoor location information and biometrics, which easily monitors that a quarantined person is out of a quarantine site. According to the present invention, a system server (11), a quarantined person terminal (12), and a monitoring server (13) are connected through a network. The quarantined person terminal (12) includes a biometric module (31), an indoor location information collection module (32), and a GPS (33). The GPS (33) collects location information of the quarantined person terminal (12). The biometric module (31) checks whether the quarantined person terminal (12) is operated by a registered quarantined person by using a biometric sensor to transmit whether the quarantined person terminal is operated by the registered quarantined person to the system server (11). The indoor location information collection module (32) collects indoor location information collected from the quarantined space of the quarantined person and transmits the collected information to the system server (11). The system server stores the quarantined information transmitted from the quarantined person terminal (12) in a quarantined person database (21). The biometric information of the quarantined person is stored in a biometric information database (23) in the quarantined person database (21) and a quarantined person location information database (24) stores the location information of the quarantined person and the indoor location information. When a biometric information mismatch message is received from the quarantined person terminal (12) or a biometric information identical determination module (34) determines that the quarantined person is a different person from the registered person, a biometric information inconsistency message is transmitted to the monitoring server (13). When an indoor location information matching determination module (35) determines that the quarantined person terminal is out of an initially registered indoor location, a quarantine site departure message is transmitted to the monitoring server (13).
Provided is an improved method of percutaneous transluminal balloon coronary angioplasty for dilating a narrowed portion of an artery. According to the method a multi-lumen inflatable balloon catheter having a predetermined balloon size and shape when inflated is introduced into the lumen of an artery in the patient and advanced until it is in the region of arterial narrowing. The balloon is then inflated for a pre-determined amount of time. According to a preferred embodiment the balloon is inflated for from about 1 to about 5 minutes. The inflated balloon deforms the adjacent narrowed portion of the artery and, in doing so, also blocks the blood flow through the artery. Into the lumen of the artery, immediately past the blockage created by the inflated balloon, an effective amount of a pharmaceutically acceptable magnesium preparation is then injected.
New antibiotics are needed due to the increasing resistance of bacteria to existing antibiotics. Helicobacter pylori (H. pylori) is a bacteria of the stomach and has been shown to cause peptic ulcers and is implicated in gastric cancer. Up to 40% of the population has H. pylori. Current treatments used to eradicate H. pylori are a combination of a number of drugs including antibiotics and drugs which reduce the acid in the stomach. These treatments are complicated and some H. pylori is resistant to the antibiotics used.

This study is the first use of Finafloxacin hydrochloride in man and will examine its safety and make a preliminary study of its effectiveness as a single agent in eradicating H. pylori. The urine of subjects will also be used to test its effectiveness in killing the bacteria which cause urinary tract infections.
Approximately 12 subjects will be included: 3 to 6 evaluable subjects for each cohort. The cycle length will be 3 weeks (21 days).
Postoperative pain is often severe following knee arthroplasty. Recently, a local infiltration analgesia (LIA) technique was developed by Drs Kerr and Kohan in Sydney, Australia. With this LIA-technique, a long-acting local anesthetic (ropivacaine), a nonsteroidal anti-inflammatory drug (ketorolac), and epinephrine are infiltrated intraoperatively and via an intraarticular catheter postoperatively. We ahve completed a study on unicompartmental knee arthroplasty and the present study is investigating total knee arthroplasties.

The primary aim of this study is to evaluate if intra- and postoperative administration of ropivacaine, ketorolac and epinephrine into the operating field would affect morphine consumption. Secondary end-points are hospital stay, pain intensity and side effects. In an attempt to assess the safety of this technique, knee function and patient satisfaction scores are assessed up to 3 months after surgery.
Patients will undergo standard resection and gastrointestinal anastomosis and will then have reinforcement of the anastomosis with MatriStem PSM. Patients undergoing esophagectomy, PG or TG will be evaluated with one routine postoperative contrast swallow study at post-operative day #4-10.
The present disclosure is related to the determination of the function of the recombinant region of pre-pro (ppTvCP4 TvCP4) as a specific exogenous cysteine protease (CPs) inhibitor, of the cathepsin L-type, of the papain superfamily for using it as active ingredient in pharmaceutical compositions to prevent or treat the Trichonoma vaginalis infection. Donation, expression, purification and right refolding are described for the recombinant pre-pro TvCP4 region (ppTvCp4r). The refolding of the purified ppTvCP4r polypeptide was verified by circular dichroism, fluorescence and gel filtration. The inhibitory effect of ppTvCP4r in this invention was tested in Trichonoma vaginalis extracts resistant to proteases using fluorogenic substrates for cysteine proteases cathepsin L type and legumin type. The inhibitory effect of ppTvCP4r on the surface proteases of living parasites, reduced the Trichonoma vaginalis hemolysis up to 50%, affecting virulence MX/a/2014/013798 PORTABLE URINE GLUCOMETER, MOUNTABLE ON TOILETS AND CONTROLLED BY A MOBILE APPLICATION The present disclosure is related to a portable urine glucometer, mountable on toilets and controlled by a mobile application which is placed in any toilet. The purpose of this device is to allow the user to measure his/her sugar level simply and painlessly, when urinating daily over the toilet where the device is located. This glucometer performs the measurement of glucose levels of urine, which is activated by a mobile and auxiliary device for constant monitoring the same in patients. It is a non-invasive device and does not require any further manipulation by the user.
Participants with untreated DLBCL will receive G-CHOP or R-CHOP in Cycle 1, followed by G/R-CHOP + glofitamab for subsequent cycles. Glofitamab will be administered using step-up dosing for Cycle 2 on Days 8 and 15, followed by single doses on Day 8 for Cycles 3-6 (up to 8). The starting dose of glofitamab for each arm may be one or more levels below the MTD/OBD determined in Part I.
There are few studies on the relationship between dietary habits and asthma-COPD overlap (ACO). In this study, we aimed to investigate the association between dietary inflammation index (DII) score and ACO. Data from the National Health and Nutrition Examination Survey (NHANES) from 1999 to 2020. The DII score was first calculated and the demographic characteristics of the grouping based on the DII quartile were assessed. The weighted logistic regression model was used to study the relationship between DII and ACO. Subgroup analysis was used to further explore the differences in different subgroups. Restricted cubic spline (RCS) plot was used to show the general trend of DII score and disease risk, and threshold effect analysis was used to determine the inflection point. In a comparison of baseline characteristics, the highest ACO prevalence was found in the fourth quartile array of people in DII. An adjusted weighted logistic regression model showed that DII was positively correlated with the incidence of ACO. Subgroup analysis showed that the association was more pronounced in women, non-Hispanics, people with cardiovascular disease, and people without diabetes. The RCS graph shows that overall, the risk of ACO increases with the increase of DII score. Threshold effect analysis showed that the inflection point was 3.779, and the risk was more significant after the DII score was greater than the inflection point value (OR 2.001, 95% CI 1.334-3.001, P < 0.001). Higher DII scores were positively associated with ACO risk. These results further support diet as an intervention strategy for ACO prevention and treatment.
Anxiety and depression are the two most common psychiatric conditions, affecting over a quarter of the population, and representing the leading cause of disability, worldwide. More than three-quarters of patients never receive treatment, and recent meta-analyses and large-scale clinical trials suggest that only about half of patients improve with treatment, with substantially poorer outcomes and adherence in patients with comorbid anxiety and depression. Given the insufficient treatment response and adherence to currently available therapies, it is important to explore novel ways of helping patients with anxiety and depression. Floatation-REST (Reduced Environmental Stimulation Therapy) is a relatively unexplored mind-body intervention for naturally reducing physiological stress by attenuating exteroceptive sensory input to the nervous system through the act of floating supine in a pool of water saturated with Epsom salt (magnesium sulfate). Over the past decade, floating has witnessed a rapid rise in popularity, with hundreds of recreational float centers opening across America. Despite the surge in public interest and consumption, there has been little research investigation Floatation-REST, especially in clinical populations. The investigators recently completed several pilot studies in patients with comorbid anxiety and depression showing that a single float session was capable of inducing a large short-term anxiolytic and antidepressant response accompanied by a substantial improvement in mood and subjective well-being. This proposal aims to follow-up on these promising preliminary findings by investigating the feasibility, tolerability, and safety of undergoing multiple sessions of Floatation-REST or an active comparison condition in 75 participants with clinical anxiety and depression. A subset of these participants will have the opportunity to select their preference with regard to float duration and frequency, providing important information for optimizing the "dose" in future trials. Since this study is aimed at examining feasibility, tolerability, and safety, the primary endpoint is adherence (as a proxy of feasibility), and the secondary outcome measures are dropout rate (as a proxy for tolerability) and adverse effects (as a proxy for safety). An exploratory aim examines the magnitude and duration of the anxiolytic and antidepressant effects of Floatation-REST at both short-term (up to 48 hours) and long-term (up to 6 months) intervals, providing an initial indication for whether any beneficial effects are sustained beyond the float experience. The results of this early phase clinical trials will help optimize the design of a future efficacy study exploring the long-term effects of Floatation-REST.
As sleep problems can impair quality of work, an online questionnaire was used to examine relationships between sleepiness and decision making while obtaining unobtrusive indices of performance. Participants (N = 344) completed the Insomnia Severity Index, Epworth Sleepiness Scale, and the Melbourne Decision Making Questionnaire in a Qualtrics survey while reporting mobile phone use. Qualtrics recorded the time and the number of clicks required to complete each page of the survey. Multiple regression indicated that insomnia was associated with daytime sleepiness and Hypervigilance, and mobile phone use before bed. Participants with moderate sleepiness required a greater number of clicks to complete the questionnaire. Greater sleepiness was associated with longer times to complete these self-assessment tasks. Clinically significant sleepiness produces changes in performance that can be detected from online responsivity. As sleepy individuals can be appreciably and quantitatively slower in performing subjective self-assessment tasks, this argues for objective measures of sleepiness and automated interventions and the design of systems that allow better quality sleep.Practitioner summary: Work can require processing of electronic messages, but 24/7 accessibility increases workload, causes fatigue and potentially creates security risks. Although most studies use people's self-reports, this study monitors time and clicks required to complete self-assessment rating scales. Sleepiness affected online responsivity, decreasing online accuracy and increasing response times and hypervigilance.
Participants will be administered a single oral dose of 20 mg of vonoprazan oral tablets on Day 1 and Day 17. Participants will also be administered single daily doses of 600 mg rifampin oral capsules on Days 3 through 18.
PURPOSE:To provide a uterus-relaxing agent free from side effects, having both uterus and bladder relaxing effects, containing, as active ingredients, a benzyl alcohol derivative and its acidadded salt. CONSTITUTION:The objective agent containing, as active ingredients, a compound of the formula and its acid-added salt. Said salt is e. g. a mineral acid (e.g. HCl, H2SO4) salt or organic acid (e. g. maleic acid, fumaric acid) salt. Both the active ingredients can be prepared into pharmaceutical(s) such as tablets, capsules, powders, granules for oral administration, injections or suppositories, etc., through conventional process using additives for the preparation to be used, in general, as medicines. The dose of the present active ingredients is normally ca. 0.01-10mg/day per adult.
Monkeypox (mpox), a zoonotic disease caused by the monkeypox virus (MPXV), poses a significant public health threat with the potential for global dissemination beyond its endemic regions in Central and West Africa. This study explores the multifaceted aspects of monkeypox, covering its epidemiology, genomics, travel-related spread, mass gathering implications, and economic consequences. Epidemiologically, mpox exhibits distinct patterns, with variations in age and gender susceptibility. Severe cases can arise in immunocompromised individuals, underscoring the importance of understanding the factors contributing to its transmission. Genomic analysis of MPXV highlights its evolutionary relationship with the variola virus and vaccinia virus. Different MPXV clades exhibit varying levels of virulence and transmission potential, with Clade I associated with higher mortality rates. Moreover, the role of recombination in MPXV evolution remains a subject of interest, with implications for understanding its genetic diversity. Travel and mass gatherings play a pivotal role in the spread of monkeypox. The ease of international travel and increasing globalization have led to outbreaks beyond African borders. The economic ramifications of mpox outbreaks extend beyond public health. Direct treatment costs, productivity losses, and resource-intensive control efforts can strain healthcare systems and economies. While vaccination and mitigation strategies have proven effective, the cost-effectiveness of routine vaccination in non-endemic countries remains a subject of debate. This study emphasizes the role of travel, mass gatherings, and genomics in its spread and underscores the economic impacts on affected regions. Enhancing surveillance, vaccination strategies, and public health measures are essential in controlling this emerging infectious disease.
Subjects will be randomized and assigned to one of the treatment groups (D2 or D3). Subjects will be dispensed a supply of 1.25 mg cholecalciferol/ergocalciferol tablets, depending on their randomization outcome. The number of pills dispensed and medication instructions will be determined by their 25OHD level and K/DOQI guidelines. Both Study personnel and subject will be blinded to randomization group.

The treatment phase will be 24 weeks in duration with lab visits every 6 weeks. All laboratory specimens will be drawn either at CCF Main hospital labs or at a CCF family Health center lab. Subjects will be have telephone interviews at week 4, 10, 16, 22 and possibly at weeks 28 and 34.
FIELD: biotechnology, medicine. SUBSTANCE: method involves preparing high-productive strain of murine hybrid cells producing monoclonal antibodies to the human platelet glycoproteins IIb-IIIa. Strain FraMon is obtained by step-by-step recloning and selection from the primary population of hybrid cells CR C64. It shows enhanced stability and high growth rate. Concentration of monoclonal antibodies in cultural fluid is 60-80 mcg/ml. FraMon antibodies inhibit human platelet aggregation completely at concentration 1-3 mcg/ml. Antibodies can be used for treatment of thrombosis, myocardium infarction, for vessel prosthesis operations. EFFECT: enhanced effectiveness of antibody production. 3 cl, 3 dwg
Participants who completed Part 1, 2, or 3 and have reached amyloid negativity (≤ 24 centiloids) in either of the Study Parts or at the OLE baseline visit will receive RO7126209 Q12W for 101 weeks. The dose level will depend on the dose level in Part 1, 2, and 3.
A system for providing on-demand functionality during a medical procedure is provided. The system comprises a first instrument comprising an instrument body and an end effector. The end effector provides a first functionality. The system further comprises a first accessory providing a second functionality. The first functionality and the second functionality are a common functionality. The system further comprises a mounting component attached to the first accessory. The mounting component is configured to interact with the instrument body to removably couple the first accessory to the first instrument to augment the first functionality with the second functionality.
Infective endocarditis, particularly after implanting valve prostheses, poses significant surgical challenges, often requiring complex interventions. We describe a case of a 37-year-old male with Staphylococcus aureus endocarditis, unsuccessfully treated with mechanical valve prostheses. Continued infection led to the destruction of the intervalvular fibrous body, necessitating a Commando procedure involving radical debridement and replacement of both aortic and mitral valves with complex patch reconstruction. Prosthesis selection remains contentious, considering recurrence risk and long-term prognosis. Our case underscores timely intervention and meticulous technique in managing such complex situations. It highlights successful strategies for treating infective endocarditis with destruction of aortomitral continuity, emphasizing the pivotal role of the Commando procedure.
Subjects in D arm (Group 2 Non-menthol) will be required to smoke Ploom HTP Tobacco HTS; R8 (120) study product at least 5 times per day ad libitum from 07:00 through 23:00. There will be 60 subjects assigned to this arm with a randomization ratio of 2.
Liposuction of a small amount of adipose tissue will be taken from each subject. Stromal Vascular Fraction (SVF) will be disassociated within the GID SVF-2 from the autologous adipose tissue to be injected into a small (approximately 2x2cm) area of the scalp in men or women with androgenic alopecia.
Prevention and treatment of accelerated loss of cognitive faculties, esp. Alzheimer's disease, comprises admin. of a K group vitamin or a substance which influences its transport or activates its regeneration. Also claimed is a risk assessment method w.r.t. the occurrence of accelerated loss of cognitive faculties or Alzheimer's disease comprising admin. of a substance which determines a) the vitamin K concn. or the content of carboxylated glutamate gps. in vitamin K-dependent proteins in body fluids (including blood) or b) the concn. of  psi -carboxy-glutamate in such body fluids or body excretions.